

# THE DEVELOPMENT AND EVALUATION OF LYCOPENE CO-DELIVERED TAMOXIFEN LOADED DAMMAR GUM NANOPARTICLES TO FIGHT CANCER CELL LINE

Ashu Saini<sup>1</sup>, Neeraj Sethi<sup>2\*</sup>, Vivek Srivastava<sup>3</sup>

<sup>1</sup>Department of Biochemistry, Om Sterling Global University, Hisar

<sup>2</sup>Department of Biotechnology, Om Sterling Global University, Hisar

<sup>3</sup>Department of Botany, Dayanand College, Hisar-125001

[saini.ashu099@gmail.com](mailto:saini.ashu099@gmail.com)

[20neerajsethi@gmail.com](mailto:20neerajsethi@gmail.com)

[viveksrivastava1969@gmail.com](mailto:viveksrivastava1969@gmail.com)

\*Corresponding author email; [20neerajsethi@gmail.com](mailto:20neerajsethi@gmail.com)

## Abstract

Drug resistance is a frequent problem with chemotherapy-based cancer treatments. Secondary metabolites of plants with anticancer potential can be successfully enhanced at the nanoscale. Lycopene have a molecular formula  $C_{40}H_{56}$ . It is a tetraterpene and a carotene used in cosmetics as antiwrinkle agent, has the capacity to kill cancer cells by impeding cellular proliferation. Tamoxifen, a selective oestrogen receptor modulator, is employed to treat oestrogen receptor-positive breast cancer, reduce the risk of invasive breast cancer following surgery, or lessen the risk of breast cancer in high-risk women. To improve bioavailability and have a synergistic effect, Lycopene and TAM loaded dammar gum nanoparticles (LTDNPs) were made using oil in oil (O/O) emulsion solvent evaporation procedures. Zeta potential, a measure of a nanoparticles relative stability, was found to be -45.1 mV for LTDNPs. The percentage encapsulation efficiency values for Lycopene and TAM were found to be 70% and 76%, respectively. The LTDNPs have particles with a size between 28 and 32 nm, according to TEM. Compared to free Lycopene and TAM particles alone, the LTDNPs had far stronger anti-oxidant and anti-cancer capabilities and had sustained release. The *in vitro* experiments revealed that the combination of Lycopene, TAM, and dammar gum significantly inhibited the growth of MCF-7 cell lines

compared to Lycopene, TAM, and dammar gum together, highlighting the combination's substantial anticancer potential.

**Keywords** Dammar gum, Lycopene, Tamoxifen, Anti-cancer, Nanoparticles

## Introduction

The application of nanotechnology to the treatment of cancer opens up a completely new field of pharmaceutical study. Nanoscale drug molecules provide a novel, very effective bioactive-loaded nanoplatform to fight cancer cells. Chemotherapy is frequently used to treat a variety of cancers [1]. Contrarily, these conventional therapeutic approaches have a detrimental effect, particularly in terms of medication tolerance or resistance [2, 3]. Life-saving treatments made possible by nanotechnology are very popular these days. The bioactive compounds with improved antioxidant and anticancer capabilities at the nanometric size also show good absorption at low doses. The National Institute of Cancer in the USA has encouraged research into the potential anticancer properties of numerous plant secondary metabolites [4, 5]. Phytochemicals including Lycopene has been shown to have cytotoxic effects in the literature [6].

Recent studies have shown that the morphological properties of nanoparticles are essential for obtaining anticancer activity with few adverse effects [7]. Size, shape, and surface features of nanoparticles have an impact on their pharmacokinetic and pharmacodynamic properties.

The aglycone of saponins and free carboxylic acid are both types of Lycopene triterpenoid) [8]. It causes glucocorticoid receptor modification in human breast cancer cell lines (Michigan Cancer Foundation-7) and reduces Bcl2 (anti-apoptotic proteins) levels [9, 10]. Due to its low level of toxicity and natural origin, Lycopene is frequently used in pharmaceutical formulations that can be applied topically and taken orally [11, 12].

The optimal characteristics to take into account when choosing an agent for drug encapsulation are biodegradability and biocompatibility [13, 14]. Dammar gum is a new encapsulation ingredient used for medicinal action, and studies have shown that as gum concentration is increased, encapsulation effectiveness increases proportionally [15].

A type of hormonal therapy is a selective oestrogen receptor modulator (SERM), like tamoxifen. The drug binds to hormone receptors, which are particular proteins found on breast cancer cells.

Once the medication has reached the cells, it blocks the cancer's access to the hormones it requires for growth and spread. [16,17]. Since the Food and Drug Administration (FDA) approved tamoxifen in 1998, it has grown to be one of the most frequently prescribed therapies for breast cancer. It is a nonpolar molecule with two primary mechanisms of action: (1) competing with 17-estradiol (E2) at the receptor site to stop E2 from causing breast cancer; and (2) binding DNA following metabolic activation and initiating carcinogenesis [18,19]. It has anticancer efficacy due to its structural affinity for the cell membrane and adjuvant hormonal therapy [20].

Creating a Lycopene co-delivered TAM polymeric nanoplatform to boost bioavailability, foster synergism, and reduce adverse effects was the aim of the current work. The encapsulation of TAM and Lycopene allows for the longer release of the polymeric nanoparticles and enhanced therapeutic efficacy at low dosage.

## **Materials and Methods**

### ***Materials***

Gum dammar was bought from MP Biomedicals, LLC, a French firm. We purchased tamoxifen and Lycopene (>90%) from Sigma Aldrich in India. The cell line MCF-7-Human breast cancer cells was donated by the National Centre for Cell Science (NCCS), located in Pune. All of the chemicals used in this study were of the analytical kind.

### **Lycopene & TAM loaded Dammar gum nanoparticles preparation (LTDNPs)**

The LTDNPs were produced by solvent evaporation in an oil-in-oil emulsion [21]. 150 mg of dammar gum, 80 mg of Lycopene, and 25 mg of TAM were dissolved in 200 ml of propanol. The aforementioned solution was mixed with 30 mg of magnesium stearate and stirred magnetically at 1200 rpm for 40 minutes. 80 cc of liquid paraffin oil was gradually added to the mixture after the mixture had been continuously stirred for 8 hours at 1200 rpm at 40 C and centrifuged for 40 minutes at 10000 rpm at 4 C. The pellet was separated, placed in a cryoprotectant (5% w/v D-Mannitol), and then dried using a freeze-drying technique.

### ***Characterization of synthesized LTDNPs***

The Zetasizer Nano ZS-90 was used to assess the average size and size distribution (polydispersity index) of the optimized nanoformulation of LTDNPs. After a 40-minute centrifugation at 10000 rpm (4 °C), the supernatant containing the unbound medication was collected and analysed by HPLC. The encapsulation efficiency was (Total Drug-Unbound Drug/Total Drug), where the formula for percent entrapment efficiency is 100.

The size and shape of the optimized batch of LTDNPs were studied under a transmission electron microscope. In the range of 4500-500  $\text{cm}^{-1}$ , the Fourier transform infrared spectrophotometer was used to evaluate the FTIR analysis of Lycopene, TAM, dammar gum, and LTDNPs.

### ***In vitro release profile of LTDNPs***

The dialysis sac technique was used to study the release profile. Water (10 ml), ethanol (25%) phosphate buffer (0.1 M) saline pH 7.4 were added to a dialysis sac containing 10 mg of Lycopene co-delivered TAM loaded dammar gum nanoparticles. The mixture was then continuously stirred at 100 rpm at a constant temperature of 37 °C [21]. One ml samples were taken, collected, and evaluated using HPLC Lycopene (219.9 nm, 5.58 min.) and TAM (256 nm, 7.01 min.) at regular intervals of 1, 2, 3, 6, 12, and 24 hours.

### ***Antioxidant activity***

The antioxidant ability of Lycopene, TAM, Dammar Gum, and LTDNPs was evaluated using the DPPH test [22]. The 3.9 mg/100 ml of methanol was uniformly mixed with the free radical DPPH. Pure Lycopene, TAM, Dammar Gum, and LTDNPs were incubated with DPPH for 30 minutes in the dark to examine the inhibition of DPPH in duplicate runs. A UV spectrophotometer was used to quantify the absorption peak at 517 nm. Blank dammar NPs were used as the negative control, while pure Lycopene and TAM were used as the positive controls. The percentage of DPPH inhibition by pure Lycopene, TAM, and LTDNPs was calculated using the following formula:

$$\text{Percent antioxidant activity} = \frac{\text{Absorbance of control} - \text{Absorbance of sample X}}{\text{Absorbance of control}} \times 100$$

***In-vitro assay for cytotoxic activity (MTT assay)***

Incubated at a temperature of 370 °C and in an atmosphere with 5% CO<sub>2</sub>, cell lines (both healthy and malignant) were cultured in media supplemented with inactivated FBS solution (10%), antibiotic streptomycin concentration of 80 l/ml, and antibiotic penicillin concentration of 80 l/ml [21, 23]. Subcultures were carried out employing 0.25% trypsin solutions in sterile laminar air flow after reaching 75% confluence. In 96-well plates with 104 cells per 100 l in each well, cell seeding was examined. The growth characteristic pattern of each cell line was evaluated to gauge its density. After 8 hours of incubation, the wells were subjected to three days (in triplicate) of treatment with various doses of LTDNPs (0.1-500 g/ml) and Lycopene.

After the cells had been grown, the medium was replaced with 3 l of MTT solution (5 mg/ml), and the mixture was then incubated for 3 h. The percentage of metabolically active cells was compared to untreated controls based on the mitochondrial conversion of 3-(4, 5-dimethylthiazol-2-yl) 2, 5 diphenyltetrazolium bromide (MTT) to Formazan crystals. After dissolving the formazan crystals in DMSO, the mixture's absorbance at 570 nm was measured. In the MTT assay, pure OA and TAM were employed as the gold standard to evaluate the anticancer effectiveness of OTDNPs against the human breast cancer cell line MCF-7. The percentages of cytotoxicity (2) and inhibition of cell growth (1) were calculated using the next procedure.

$$\% \text{viability} = (A_{Tr} - A_{Bi}) / (A_{Ct} - A_{Bi}) \times 100 \dots\dots\dots (1)$$

Where A<sub>Tr</sub> = Absorbance for treated cells (drug); A<sub>Bi</sub> = Absorbance for blank

A<sub>Ct</sub> = Absorbance for control (untreated)

$$\% \text{cytotoxicity} = 100 - \text{Percent cell survival (\%)} \dots\dots\dots (2)$$

**Results and Discussion*****Particle size and Zeta Potential***

The LTDNPs' zeta potential and particle size were examined. The created nanoformulation was discovered to have a zeta potential value of -45.1 mV and a rather steady size for LTDNPs of 198.6 nm (Figs. 1 and 2).

### ***Encapsulation efficiency***

The % encapsulation efficiency number is influenced by the method utilized, the chemical composition of the encapsulating materials, and the dielectric constant of the medium used to create nanoparticles [21, 24]. The percentage of bound drug was calculated using the HPLC analysis of supernatant containing unbound drug, and the findings were 70% for Lycopene and 76% for TAM (Fig. 5). Lycopene and TAM are non-polar hydrophobic compounds. They dissolve relatively easily in propanol-based gum solution. Dammar gum has a great affinity for Lycopene and TAM because it is hydrophobic. The medication was better encapsulated in dammar gum as a result of the similar natural affinity.

### ***Morphological characterization of LTDNPs by TEM***

The LTDNPs were uniformly spherical, segregated, and ranged in size from 35 to 64 nm, as shown by Transmission Electron Microscopy (Figure 3). According to experimental studies, the size of the nanoparticles examined by TEM and PSA differed. This is due to the fact that PSA operates under the assumption that the ions of nanoparticles are fluidized around them, but TEM operates under the assumption that a particle's size will decrease in a solitary, dry atmosphere. The release rate of medications is influenced by the size of nanoscale particles [25, 26]. Depending on their size and shape, NPs are transported to various human organs at varied concentrations. Nanoparticles' relative stability, biocompatibility with the environment of the body, and ability to pass through cell membranes are all influenced by their shape and size [26]. Smaller nanoparticles are maintained in the systemic circulation for a longer period of time compared to larger nanoparticles [27].

### ***FTIR Analysis of Drug Samples***

FTIR spectroscopy is used to examine the interaction [27] and evaluate the nanoencapsulation of bioactive substances [28]. The FTIR spectra of the pure medicines Lycopene, TAM, dammar gum, and LTDNPs are shown in Figure 4. The absorption peak bands in the FTIR spectrum of Lycopene were 3000.0 cm<sup>-1</sup> and 2401 cm<sup>-1</sup> for the terminal -CH<sub>3</sub> groups and 3412 cm<sup>-1</sup> for the

-OH group. The distinctive absorption band for =C-H stretching at 2876 cm<sup>-1</sup> and for C=C ring stretching at 1600 cm<sup>-1</sup> were visible in the FTIR spectra of TAM in Figure 4B. Wave number values at 1501 cm<sup>-1</sup> and 3401 cm<sup>-1</sup> indicated -NH<sub>2</sub> structure. The peak at 3412 cm<sup>-1</sup> for the -OH stretch and the peak at 2900 cm<sup>-1</sup> for the aliphatic -CH stretch, respectively, are shown in Figure 4 C's FTIR analysis of dammar gum. Figure 4D shows the FTIR spectra of LTDNPs, which show variations between wave numbers 3409 cm<sup>-1</sup>, 1400 cm<sup>-1</sup>, 2458 cm<sup>-1</sup>, and 2901 cm<sup>-1</sup>. The IR stretching vibration zones for functional groups like OH, C=C Stretch, CH<sub>3</sub> Stretch, and C-H Stretch are located here. Dammar gum's OH and the drug's C-H combine to generate dipole-dipole interactions, hydrogen bonds, and weak Van der Waals forces, among other weak physical bonds. The drugs' and excipients' FTIR spectra showed unique peaks. The change in the bands and decrease in peak intensity indicated that TAM, Lycopene, and dammar gum were physically interacting.

### ***In-vitro drug release***

The continuous release of bioactive compounds from nanoparticles cages protects them from rapid metabolism and oxidation [29]. Figure 5 displays the in vitro drug release characteristics of Lycopene, TAM, and LTDNPs. The drug was highly effectively and efficiently entrapped in dammar gum, which resulted in LTDNPs showing sustained drug release. The in-vitro results on drug release showed that 90% of pure Lycopene and 95% of pure TAM were only released in 5 hours. 16% Lycopene and 17.81% TAM were released by the LTDNPs one hour after administration. LTDNPs released 75% of Lycopene and 84% of TAM after 24 hours. Because Lycopene and TAM are hydrophobic (nonpolar), LTDNPs' total drug release showed sustained release characteristics of Lycopene and TAM throughout time. In order to guarantee a continual release of the Lycopene and TAM particles, dammar gum also creates a dense matrix with a thick, sturdy wall around them.

### ***Anti-oxidant activity***

To quantitatively evaluate the antioxidant activity/potency of compounds that have been encapsulated, the DPPH analysis approach is used [31]. The 1,1-diphenyl-2-picrylhydrazyl (DPPH) stable free radical absorbs light to show excitation and emits a deep violet colour when it does. It has unpaired electrons that have distributed randomly throughout the molecule. At 517

nm, it exhibits absorption [32]. When a DPPH solution is uniformly mixed with a molecule that has the potential to donate (oxidizing nature) a hydrogen atom, the violet colour disappears. It is well known that Lycopene and TAM have antioxidant properties. When the antioxidant molecules Lycopene and TAM were dissolved in DPPH, a stable non-radical version of DPPH was created, turning the violet colour to pale yellow. Consequently, the absorption band contracted. Inhibiting DPPH can happen when labile hydrogen atoms in the Lycopene and TAM are released. The LTDNPs wide surface area and small nanometric dimension shielded Lycopene and TAM from oxidation during dark incubation, leading to a higher percentage of DPPH inhibition than Lycopene and TAM alone.

### ***Anti-cancer activity***

The improved cytotoxic efficacy and powerful anticancer characteristics of the nanoparticles depicted in Figures 6 were greatly enhanced by their higher surface area [33]. Nanoparticles in the 100 nm range are more able to infiltrate cancer cells quickly or effectively due to the retention effect and increased vascular penetration [34]. As a result, NPs' efficiency against cancer cell lines depends on their size [35,36]. Nanoscale particles can more efficiently reach the cancer cells. In the current study, LTDNPs' anti-cancer action was revealed to be more effective than pure active drug alone. In an in vitro experiment, Lycopene and TAM coupled with dammar gum more successfully inhibited the development of MCF-7 than the free drugs did. Data also shows the IC<sub>50</sub> values (g/ml) of synthesized nanoparticles. When compared to the traditional drugs TAM and Lycopene alone, the optical microscope examination on the cancer cell line MCF-7 showed that LTDNPs had a potent anticancer impact with an IC<sub>50</sub> of 3.94 g/ml. The potent anticancer impact of LTDNPs was primarily attributed to the synergistic interaction between TAM and Lycopene in these drugs.

### **Conclusions**

Nanotechnology-based medicines are now able to successfully address and treat a variety of ailments thanks to significant advancements in the drug formulation sector. One use of nano-drug delivery is the systems for delivering nanoparticles with bigger payloads, such as dual drug delivery to give synergistic effects of secondary metabolites with pharmaceuticals at therapeutic



size. Despite the large number of anticancer medication compounds that have been identified, the main drawbacks of these therapeutic molecules are their low bioavailability, short half-lives in the body, and potential for tolerance and resistance. Designing new nanoformulations consisting of more efficient excipients is essential in order to increase solubility in water, bioavailability to blood from the intestine, therapeutic potential to kill cancer cell lines, and decrease dosage. Due to its synergistic antioxidant and anticancer capabilities, the current work's novel nanoformulation, which includes Lycopene acid co-delivered TAM loaded dammar gum nanoparticles, has emerged as a viable chemical to successfully combat cancer.

## REFERENCES

1. Ilic, D., Forbes, K. M., & Hased, C. (2011). Lycopene for the prevention of prostate cancer. *Cochrane database of systematic reviews*, (11).
2. Zhang, L. G., Leong, K., & Fisher, J. P. (Eds.). (2022). *3D bioprinting and nanotechnology in tissue engineering and regenerative medicine*. academic press.
3. Ferdows, B. E., Patel, D. N., Chen, W., Huang, X., Kong, N., & Tao, W. (2022). RNA cancer nanomedicine: nanotechnology-mediated RNA therapy. *Nanoscale*, *14*(12), 4448-4455.
4. Seca, A. M., & Pinto, D. C. (2018). Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. *International journal of molecular sciences*, *19*(1), 263.
5. Mirahmadi, M., Azimi-Hashemi, S., Saburi, E., Kamali, H., Pishbin, M., & Hadizadeh, F. (2020). Potential inhibitory effect of lycopene on prostate cancer. *Biomedicine & Pharmacotherapy*, *129*, 110459.
6. Milind, P., Sushila, K., & Neeraj, S. (2013). Understanding gout beyond doubt. *International Research Journal of Pharmacy*, *4*(9), 25-34.
7. Ahmad, M. Z., Rizwanullah, M., Ahmad, J., Alasmay, M. Y., Akhter, M. H., Abdel-Wahab, B. A., ... & Haque, A. (2022). Progress in nanomedicine-based drug delivery in designing of chitosan nanoparticles for cancer therapy. *International Journal of Polymeric Materials and Polymeric Biomaterials*, *71*(8), 602-623.


8. Kaura, S., Parle, M., Insa, R., Yadav, B. S., & Sethi, N. (2022). Neuroprotective effect of goat milk. *Small Ruminant Research*, 214, 106748.
9. Sethi, N., Bhardwaj, P., Kumar, S., & Dilbaghi, N. (2019). Development and Evaluation of Ursolic Acid Co-Delivered Tamoxifen Loaded Dammar Gum Nanoparticles to Combat Cancer. *Advanced Science, Engineering and Medicine*, 11(11), 1115-1124.
10. Sethi, N., Bhardwaj, P., Kumar, S., & Dilbaghi, N. (2019). Development And Evaluation Of Ursolic Acid Loaded Eudragit-E Nanocarrier For Cancer Therapy. *International Journal Of Pharmaceutical Research (09752366)*, 11(2).
11. Suman, J., Neeraj, S., Rahul, J., & Sushila, K. (2014). Microbial synthesis of silver nanoparticles by *Actinotalea* sp. MTCC 10637. *American Journal of Phytomedicine and Clinical Therapeutics*, 2, 1016-23.
12. Vivek, Vibhor, Neeraj Sethi, and Sushila Kaura. "Green synthesis and evaluation of antibacterial activity of zinc nanoparticles from *Calotropis procera* leaves." (2022).
13. Kaur, H., Ahuja, M., Kumar, S., & Dilbaghi, N. (2012). Carboxymethyl tamarind kernel polysaccharide nanoparticles for ophthalmic drug delivery. *International Journal of Biological Macromolecules*, 50(3), 833-839.
14. Barber, N. J., & Barber, J. (2002). Lycopene and prostate cancer. *Prostate Cancer and Prostatic Diseases*, 5(1), 6-12.
15. Van Aarssen, B. G. K., Cox, H. C., Hoogendoorn, P., & De Leeuw, J. W. (1990). A cadinene biopolymer in fossil and extant dammar resins as a source for cadinanes and bicadinanes in crude oils from South East Asia. *Geochimica et Cosmochimica Acta*, 54(11), 3021-3031.
16. Giovannucci, E., Rimm, E. B., Liu, Y., Stampfer, M. J., & Willett, W. C. (2002). A prospective study of tomato products, lycopene, and prostate cancer risk. *Journal of the National Cancer Institute*, 94(5), 391-398.
17. Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. *New England Journal of Medicine*, 339(22), 1609-1618.
18. Jordan, V. C. (2003). Tamoxifen: a most unlikely pioneering medicine. *Nature reviews Drug discovery*, 2(3), 205-213.

19. Bradley, R., Braybrooke, J., Gray, R., Hills, R. K., Liu, Z., Pan, H., & Swain, S. M. (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. *The Lancet Oncology*, 23(3), 382-392.
20. Shrivastava, N., Parikh, A., Dewangan, R. P., Biswas, L., Verma, A. K., Mittal, S., & Baboota, S. (2022). Solid Self-Nano emulsifying nanoplatform loaded with Tamoxifen and Resveratrol for treatment of breast cancer. *Pharmaceutics*, 14(7), 1486.
21. Iqbal, M., Zafar, N., Fessi, H., & Elaissari, A. (2015). Double emulsion solvent evaporation techniques used for drug encapsulation. *International journal of pharmaceutics*, 496(2), 173-190.
22. Antolovich, M., Prenzler, P. D., Patsalides, E., McDonald, S., & Robards, K. (2002). Methods for testing antioxidant activity. *Analyst*, 127(1), 183-198.
23. Meerloo, J. V., Kaspers, G. J., & Cloos, J. (2011). Cell sensitivity assays: the MTT assay. In *Cancer cell culture* (pp. 237-245). Humana Press.
24. Dhanda, P., Sura, S., Lathar, S., Shoekand, N., Partishtha, H., & Sethi, N. (2022). Traditional, phytochemical, and biological aspects of Indian spider plant.
25. Mayeen, A., Shaji, L. K., Nair, A. K., & Kalarikkal, N. (2018). Morphological characterization of nanomaterials. In *Characterization of Nanomaterials* (pp. 335-364). Woodhead Publishing.
26. Yao, L., Ou, Z., Luo, B., Xu, C., & Chen, Q. (2020). Machine learning to reveal nanoparticle dynamics from liquid-phase TEM videos. *ACS central science*, 6(8), 1421-1430.
27. Ou, H., Cheng, T., Zhang, Y., Liu, J., Ding, Y., Zhen, J., ... & Shi, L. (2018). Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells. *Acta Biomaterialia*, 65, 339-348.
28. Dahan, K., Fennal, M., & Kumar, N. B. (2008). Lycopene in the prevention of prostate cancer. *Journal of the Society for Integrative Oncology*, 6(1).


29. Kumari, A., Yadav, S. K., Pakade, Y. B., Singh, B., & Yadav, S. C. (2010). Development of biodegradable nanoparticles for delivery of quercetin. *Colloids and Surfaces B: Biointerfaces*, 80(2), 184-192.
30. Kucuk, O., Sarkar, F. H., Djuric, Z., Sakr, W., Pollak, M. N., Khachik, F., ... & Wood Jr, D. P. (2002). Effects of lycopene supplementation in patients with localized prostate cancer. *Experimental Biology and Medicine*, 227(10), 881-885.
31. Sirivibulkovit, K., Nouanthavong, S., & Sameenoi, Y. (2018). based DPPH assay for antioxidant activity analysis. *Analytical sciences*, 34(7), 795-800.
32. Goupy, P., Dufour, C., Loonis, M., & Dangles, O. (2003). Quantitative kinetic analysis of hydrogen transfer reactions from dietary polyphenols to the DPPH radical. *Journal of Agricultural and Food Chemistry*, 51(3), 615-622.
33. Chen, Z., Tai, Z., Gu, F., Hu, C., Zhu, Q., & Gao, S. (2016). Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. *European Journal of Pharmaceutics and Biopharmaceutics*, 107, 130-141.
34. Xu, Z., Chen, L., Gu, W., Gao, Y., Lin, L., Zhang, Z., ... & Li, Y. (2009). The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. *Biomaterials*, 30(2), 226-232.
35. Siegler, E. L., Kim, Y. J., & Wang, P. (2016). Nanomedicine targeting the tumor microenvironment: Therapeutic strategies to inhibit angiogenesis, remodel matrix, and modulate immune responses. *Journal of Cellular Immunotherapy*, 2(2), 69-78.
36. Tammina, S. K., Mandal, B. K., Ranjan, S., & Dasgupta, N. (2017). Cytotoxicity study of Piper nigrum seed mediated synthesized SnO<sub>2</sub> nanoparticles towards colorectal (HCT116) and lung cancer (A549) cell lines. *Journal of Photochemistry and Photobiology B: Biology*, 166, 158-168.
37. Barua, S., & Mitragotri, S. (2014). Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. *Nano Today*, 9(2), 223-243.

38. Li, S., Feng, X., Wang, J., Xu, W., Islam, M. A., Sun, T., & Chen, X. (2019). Multiantigenic nanoformulations activate anticancer immunity depending on size. *Advanced Functional Materials*, 29(49), 1903391.
39. Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017). Nanoformulations for combination or cascade anticancer therapy. *Advanced drug delivery reviews*, 115, 3-22.


**Figure 1. PSA image of LTDNPs**



**Figure 2. Zeta potential of LTDNPs**



**Figure 3: TEM image of LTDNPs**



**Figure 4. The FTIR spectra of pure drug (A) Lycopene, (B) TAM, (C) Dammar gum, (D) LTDNPs**




Figure 5. In-vitro release study




Figure 6. Optical microscope images of Cytotoxic effect of Lycopene (B1), TAM (F1) and LTDNPs (N1), MCF-7 cell lines after 24 h.

